Stereotaxis Completes Installation of the World’s 1st Genesis Robotic Magnetic Navigation Systems to Treat Heart Rhythm Disorders at Helsinki University Hospital in Finland and Banner – University Medicine Heart Institute in Phoenix, Arizona

Stereotaxis today announced it has completed installations of the world’s first Genesis Robotic Magnetic Navigation systems to treat heart rhythm disorders at Helsinki University Hospital in Finland and Banner – University Medicine Heart Institute in Phoenix, Arizona.

“The clinical benefits of robotics in electrophysiology have been extensively documented at our hospital over many years,” said Dr. Pekka Raatikainen, Chief of Electrophysiology and Pacing at the Heart and Lung Center at Helsinki University Central Hospital. “With the adoption of the first Genesis systems in the world, we are proud to be a pioneer in the process of advancing robotic technology for the benefits of patients and the medical community.”

“The capabilities of robotics are growing at a rapid rate, moving us toward a paradigm shift in our practice,” said Dr. J. Peter Weiss, Director of Ventricular Arrhythmia Management and Robotics at Banner – University Medicine Heart Institute. “I am extremely excited to play a part in bringing this advanced technology to our community of patients and heart rhythm specialists throughout Phoenix and beyond.”

Stereotaxis notes the Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias, abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, certain arrhythmias can significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. The Genesis RMN® system provides the established benefits and reliability of RMN in a highly innovative architecture that is faster, smaller, lighter, and more flexible. Adopting the Genesis RMN system reflects a commitment to using the most advanced technologies to enhance patient care.

“Patients with medical conditions from the most complex to the most common seek us out for care in part because we remain on the cutting edge in technology and safety,” said Kristi McShay, Assistant Vice President for the Cardiovascular Line at Banner Health. “We are pleased to be the first in the nation to offer this new generation of robotics for treating heart rhythm disorders.”

“This technology allows us to positively address the increasing number of patients with complex arrhythmias. In addition, it provides us a competitive advantage to other Nordic centers concerning education and learning,” said Antti Vento, Medical Director of Helsinki Heart and Lung Center.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”